

Financial news for ESPR dated on 2020-06-04: Esperion Announces Commercial Availability Of NEXLIZET Tablets And Ushers In New Era Of Oral Combination Medicine For LDL-Cholesterol Lowering

Financial news for ESPR dated on 2020-06-02: The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To \$500M In Biotechs

Financial news for ESPR dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for ESPR dated on 2020-05-07: Jefferies Maintains Buy on Esperion Therapeutics, Lowers Price Target to \$70

Financial news for ESPR dated on 2020-05-06: Esperion Therapeutics Q1 EPS \$(2.840) Beats \$(3.290) Estimate, Sales \$1.840M Beat \$520.000K Estimate

Financial news for ESPR dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for ESPR dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for ESPR dated on 2020-04-20: Esperion Announces Agreement With Otsuka Pharmaceutical Co., Ltd. For Development And Commercialization Of NEXLETOL And NEXLIZET Tablets In Japan; Esperion To Receive \$60M Up Front, Up To \$510M In Milestones

Financial news for ESPR dated on 2020-04-16: Northland Capital Markets Maintains Market Perform on Esperion Therapeutics, Lowers Price Target to \$42

Financial news for ESPR dated on 2020-04-06: Esperion Therapeutics shares are trading higher after the company announced European Commission approval of its NILEMDO tablet.

Financial news for ESPR dated on 2020-04-06: Esperion Announces European Commission Approval of the NILEMDO Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia, Says Will Receive \$150M Milestone Payment Upon First Commercial Sale

Financial news for ESPR dated on 2020-04-01: B of A Securities Initiates Coverage On Esperion Therapeutics with Buy Rating, Announces Price Target to \$50

Financial news for ESPR dated on 2020-03-31: The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions

Financial news for ESPR dated on 2020-03-30: Esperion Reports Commercial Availability Of NEXLETOL Tablet

Financial news for ESPR dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for ESPR dated on 2020-03-17: Citigroup Upgrades Esperion Therapeutics to Buy

Financial news for ESPR dated on 2020-03-02: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for ESPR dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for ESPR dated on 2020-02-28: JP Morgan Maintains Neutral on Esperion Therapeutics, Raises Price Target to \$47

Financial news for ESPR dated on 2020-02-27: Esperion Therapeutics Q4 EPS \$(2.26) Down From \$(2.24) YoY

Financial news for ESPR dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for ESPR dated on 2020-02-26: Esperion Reports FDA Approval Of NEXLIZET Tablet Once-Daily For Non-Statin LDL-Cholesterol Lowering Medicine

Financial news for ESPR dated on 2020-02-26: Esperion Therapeutics Receives FDA Approval Of Nexlizet

Financial news for ESPR dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for ESPR dated on 2020-02-24: Needham Maintains Strong Buy on Esperion Therapeutics, Raises Price Target to \$158

Financial news for ESPR dated on 2020-02-24: A Peek Into The Markets: Dow Futures Slump Over 700 Points As COVID-19 Spreads Globally

Financial news for ESPR dated on 2020-02-24: Northland Securities Downgrades Esperion Therapeutics to Market Perform

Financial news for ESPR dated on 2020-02-24: 94 Biggest Movers From Friday

Financial news for ESPR dated on 2020-02-24: 8 Stocks To Watch For February 24, 2020

Financial news for ESPR dated on 2020-02-21: Esperion Press Release Confirms FDA Approval Of NEXLETOL

Financial news for ESPR dated on 2020-02-21: Esperion Therapeutics Shares Dip Lower As Traders Circulate Label For NEXLETOL

Financial news for ESPR dated on 2020-02-21: Esperion Therapeutics Receives FDA Approval For NEXLETOL

Financial news for ESPR dated on 2020-02-21: The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

Financial news for ESPR dated on 2020-02-18: 30 Stocks Moving in Tuesday's Pre-Market Session

Financial news for ESPR dated on 2020-02-16: The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions

Financial news for ESPR dated on 2020-02-14: The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

Financial news for ESPR dated on 2020-02-14: Citigroup Downgrades Esperion Therapeutics to Neutral, Raises Price Target to \$82

Financial news for ESPR dated on 2020-02-13: Stocks That Hit 52-Week Highs On Thursday

Financial news for ESPR dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for ESPR dated on 2020-02-12: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ESPR dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for ESPR dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ESPR dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for ESPR dated on 2020-02-03: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

Financial news for ESPR dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for ESPR dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for ESPR dated on 2020-01-22: 116 Healthcare Stocks Moving In Wednesday's Session

Financial news for ESPR dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for ESPR dated on 2020-01-07: The Daily Biotech Pulse: Xeris Jumps On

Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering

Financial news for ESPR dated on 2020-01-03: The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

Financial news for ESPR dated on 2020-01-02: The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe

Financial news for ESPR dated on 2019-12-27: Stocks That Hit 52-Week Highs On Friday

Financial news for ESPR dated on 2019-12-27: The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

Financial news for ESPR dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for ESPR dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for ESPR dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for ESPR dated on 2019-12-17: Esperion Therapeutics Option Alert: Jan 17 \$55 Calls at the Ask: 500 @ \$1.65 vs 361 OI; Ref=\$51.325

Financial news for ESPR dated on 2019-11-19: 72 Biggest Movers From Yesterday

Financial news for ESPR dated on 2019-11-17: Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at AHA 2019 Scientific Sessions

Financial news for ESPR dated on 2019-11-12: Esperion Highlights Publication In Journal Of American Medical Association Of Bempedoic Acid Phase 3 Study 2 Results

Financial news for ESPR dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for ESPR dated on 2019-11-06: Esperion Therapeutics Q3 EPS \$(2.52) Misses \$(1.95) Estimate, Sales \$981K Beat \$900K Estimate

Financial news for ESPR dated on 2019-09-18: Stifel Nicolaus Maintains Buy on Esperion Therapeutics, Lowers Price Target to \$70

Financial news for ESPR dated on 2019-09-16: Benzinga's Top Upgrades, Downgrades For September 16, 2019

Financial news for ESPR dated on 2019-09-16: Goldman Sachs Upgrades Esperion Therapeutics to Neutral, Lowers Price Target to \$45

Financial news for ESPR dated on 2019-09-05: The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug

Financial news for ESPR dated on 2019-09-05: Esperion Highlights Completion Of Patient Enrollment In Global CLEAR Cardiovascular Outcomes Trial For Bempedoic Acid

Financial news for ESPR dated on 2019-09-04: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ESPR dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for ESPR dated on 2019-08-29: 23 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for ESPR dated on 2019-08-29: The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings

Financial news for ESPR dated on 2019-08-20: Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

Financial news for ESPR dated on 2019-08-08: Esperion Therapeutics Earlier Reported Q2 EPS \$(2.01) Misses \$(1.86) Estimate, Sales \$982K Beat \$930K Estimate; Expects Full-Year 2019 Net Increase In Cash Of Approximately \$90 To \$100 Million

Financial news for ESPR dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy

Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for ESPR dated on 2019-06-26: Esperion Shares Now Open For Trade, But Not Yet Seeing Updated Last Price

Financial news for ESPR dated on 2019-06-26: Esperion Shares To Resume Trade At 4:40 p.m. EDT

Financial news for ESPR dated on 2019-06-26: Esperion Says Initial Mid-Single Digit Repayment Rate On US Sales To Step Down To Less Than 1% Upon Certain Sales Milestones

Financial news for ESPR dated on 2019-06-26: Esperion Has Reacquired 100% Of Sales Rights Upon Repayment Completion

Financial news for ESPR dated on 2019-06-26: UPDATE: Esperion To Receive \$125M Upfront Payment, \$25M Upon FDA Approval, \$50M At Esperion's Option After Launch

Financial news for ESPR dated on 2019-06-26: Esperion Reports \$200M Funding Deal With Oberland

Financial news for ESPR dated on 2019-06-26: Esperion Shares Halted News Pending

Financial news for ESPR dated on 2019-05-29: Benzinga's Top Upgrades, Downgrades For May 29, 2019

Financial news for ESPR dated on 2019-05-29: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ESPR dated on 2019-05-29: Goldman Sachs Downgrades Esperion Therapeutics to Sell, Announces \$50 Price Target

Financial news for ESPR dated on 2019-05-08: Esperion Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for ESPR dated on 2019-05-08: Esperion Therapeutics Q1 EPS \$3.07 Beats \$0.97 Estimate, Sales \$145.42M Beat \$79.03M Estimate

Financial news for ESPR dated on 2019-05-07: 44 Biggest Movers From Yesterday

Financial news for ESPR dated on 2019-05-06: Esperion Therapeutics Shares Tick Higher On Heavy Volume Over Last Few Mins. As Hearing Bank Of America Upgraded Stock

Financial news for ESPR dated on 2019-05-06: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for ESPR dated on 2019-05-06: Small-Cap Biotech Esperion Surges On FDA Acceptance Of Cholesterol Drug Applications

Financial news for ESPR dated on 2019-05-06: Esperion Therapeutics shares are trading higher after the FDA accepted the company's NDAs for Bempedoic Acid and the Ezetimibe combination tablet.

Financial news for ESPR dated on 2019-05-06: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for ESPR dated on 2019-05-05: Esperion Announces FDA Acceptance of NDAs for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review

Financial news for ESPR dated on 2019-04-26: Benzinga's Top Upgrades, Downgrades For April 26, 2019

Financial news for ESPR dated on 2019-04-26: Goldman Sachs Upgrades Esperion Therapeutics, Inc. - Common Stock to Neutral

Financial news for ESPR dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for ESPR dated on 2019-04-01: Esperion Highlights Results From Phase 3 Trial Published In Journal of the American Heart Association: Showed 'Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant'

Financial news for ESPR dated on 2019-03-23: A New ETF For An Untapped Real Estate Market

Financial news for ESPR dated on 2019-03-20: 70 Biggest Movers From Yesterday

Financial news for ESPR dated on 2019-03-18: Esperion Reports Late-Breaking Publication Of Final Results Of Bempedoic Acid Pivotal Phase 3 Study 2 At American College of Cardiology 2019 Scientific Sessions

Financial news for ESPR dated on 2019-03-13: Esperion Highlights Publication Of Bempedoic Acid Study 1 Results In The New England Journal Of Medicine

Financial news for ESPR dated on 2019-03-13: 5 Biggest Price Target Changes For Wednesday

Financial news for ESPR dated on 2019-03-13: Benzinga's Top Upgrades, Downgrades For March 13, 2019

Financial news for ESPR dated on 2019-03-13: JP Morgan Upgrades Esperion Therapeutics to Neutral, Raises Price Target to \$47

Financial news for ESPR dated on 2019-03-04: Esperion Announces Presentation Of Bempedoic Acid Pivotal Phase 3 Study 2 Results In Late-Breaking Clinical Trial Session At American College Of Cardiology 2019 Scientific Sessions

Financial news for ESPR dated on 2019-02-28: Esperion Therapeutics Q4 EPS \$(2.24) Misses \$(1.42) Estimate

Financial news for ESPR dated on 2019-02-28: Esperion Announces Submissions Of Two NDAs And Official Completion Of Two MAA Validations For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Combination Tablet

Financial news for ESPR dated on 2019-02-12: 26 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ESPR dated on 2019-01-07: 58 Biggest Movers From Friday

Financial news for ESPR dated on 2019-01-04: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for ESPR dated on 2019-01-04: Esperion Reports Deal With Daiichi Sankyo Europe To Commercialize Bempedoic Acid In Europe, Will Receive \$300M Upfront, Near-Term Milestones, Will Be Eligible For \$900M In Total Milestones

Financial news for ESPR dated on 2018-12-13: Goldman Sachs Initiates Coverage On Esperion Therapeutics with Sell Rating, Announces \$45 Price Target

Financial news for ESPR dated on 2018-11-05: 74 Biggest Movers From Friday

Financial news for ESPR dated on 2018-11-01: Esperion Therapeutics Q3 EPS \$(1.86) Misses \$(1.63) Estimate

Financial news for ESPR dated on 2018-10-29: JMP Securities Out Positive On Esperion Therapeutics; Firm Says Conference Call Reaffirms 'Positive' BA Phase 3 Results And 'Compelling' Product Profile, Reaffirms Market Outperform Rating And \$153 PT

Financial news for ESPR dated on 2018-10-29: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for ESPR dated on 2018-10-29: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for ESPR dated on 2018-10-29: 71 Biggest Movers From Friday

Financial news for ESPR dated on 2018-10-28: UPDATE: Esperion Announces Bempedoic Acid Met Safety and Tolerability Endpoints in 52-Week Study

Financial news for ESPR dated on 2018-10-28: Esperion Announces Bempedoic Acid Achieved Additional 18% LDL-C Lowering in Patients on Maximally Tolerated Statins and Provided Additional 19% hsCRP Reduction in Final Pivotal Phase 3 Study

Financial news for ESPR dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for ESPR dated on 2018-10-26: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for ESPR dated on 2018-10-17: 48 Biggest Movers From Yesterday

Financial news for ESPR dated on 2018-10-16: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ESPR dated on 2018-10-16: Benzinga's Top Upgrades, Downgrades For

October 16, 2018

Financial news for ESPR dated on 2018-10-16: BTIG Research Initiates Coverage On Esperion Therapeutics with Buy Rating, Announces \$82 Price Target

Financial news for ESPR dated on 2018-10-08: The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

Financial news for ESPR dated on 2018-10-01: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for ESPR dated on 2018-08-27: Esperion Resumes Trade, Now Up ~1.85% At \$49.99/Share

Financial news for ESPR dated on 2018-08-27: Esperion Announces That Bempedoic Acid/Ezetimibe Combo Pill Achieved An Additional 35% LDL-C Lowering In Patients On Maximally Tolerated Statins, Treatment Appeared To Be As Safe And Well-Tolerated As Ezetimibe Alone

Financial news for ESPR dated on 2018-08-26: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results

Financial news for ESPR dated on 2018-08-25: Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at #ESCCongress

Financial news for ESPR dated on 2018-08-19: The Week Ahead In Biotech: Conferences, PDUFA Dates And Earnings

Financial news for ESPR dated on 2018-08-17: Benzinga's Top Upgrades, Downgrades For August 17, 2018

Financial news for ESPR dated on 2018-08-17: Citigroup Upgrades Esperion Therapeutics to Buy, Raises Price Target to \$75

Financial news for ESPR dated on 2018-08-02: Esperion Therapeutics Q2 EPS \$(1.71) Misses \$(1.70) Estimate

Financial news for ESPR dated on 2018-07-16: Insider Buys Of The Week: Energen, Esperion Therapeutics And International Flavors

Financial news for ESPR dated on 2018-07-11: Northland Securities Downgrades Esperion Therapeutics to Market Perform

Financial news for ESPR dated on 2018-07-10: Esperion Shares Fall ~2.4% Under \$44 Over Last Few Mins; Shares Now Down 2.4% For Session; Co. Currently Hosting Analyst/Investor Day

Financial news for ESPR dated on 2018-06-25: Esperion Therapeutics 10%+ Owner BB Biotech Buys 60,000 @ Avg Price: \$38.57

Financial news for ESPR dated on 2018-06-15: Esperion Therapeutics Option Alert: Jul 20 \$30 Puts at the Ask: 585 @ \$0.451 vs 666 OI; Earnings 8/7 Before Open [est] Ref=\$40.87

Financial news for ESPR dated on 2018-06-11: Biotech Target NV Buys 60,000 Of Esperion Therapeutics @\$37.79

Financial news for ESPR dated on 2018-06-07: Esperion Therapeutics 10%+ Owner BB BIOTECH AG (10%+) Buys 60,000 @ Avg Price: \$38.47

Financial news for ESPR dated on 2018-05-23: Esperion Shares Resumed Trade at 8:45, Now Up 2.3% Premarket

Financial news for ESPR dated on 2018-05-23: Esperion Therapeutics Shares To Resume Trade At 8:45 a.m. EDT

Financial news for ESPR dated on 2018-05-23: UPDATE: Esperion Says Phase 3 Study Of Bempedoic Acid 'achieved a significantly greater reduction of 25% in high-sensitivity C-reactive protein'

Financial news for ESPR dated on 2018-05-23: Esperion Therapeutics Reports Phase 3 Study Of Bempedoic Acid Met Primary Endpoint

Financial news for ESPR dated on 2018-05-23: Esperion Therapeutics Shares Halted News Pending

Financial news for ESPR dated on 2018-05-22: Esperion Shares Rebound From Monday's Weakness, Up 5.2%; Shares Fell Mon. As CEO's Absence From UBS Conference Noted By

Traders Passing Tentative Schedule Listing Co. As A Monday Presenter; Tuesday Press Release Confirms CEO To Present Wednesday

Financial news for ESPR dated on 2018-05-21: Esperion Therapeutics Shares Down 10.4%, No Apparent News: Note: CEO Set To Appear At 1:30 PM EST At UBS Global Healthcare Conference

Financial news for ESPR dated on 2018-05-04: 12 Biggest Movers Of The Week: Snap, Tenet, Wayfair And More

Financial news for ESPR dated on 2018-05-04: Credit Suisse Maintains Outperform on Esperion Therapeutics, Lowers Price Target to \$73.00

Financial news for ESPR dated on 2018-05-04: 55 Biggest Movers From Yesterday

Financial news for ESPR dated on 2018-05-03: 37 Stocks Moving In Thursday's Mid-Day Session

Financial news for ESPR dated on 2018-05-03: Esperion Shares Bouncing Off Low's Of The Day, Now Down ~25% At \$34.20/Share

Financial news for ESPR dated on 2018-05-03: 8 Biggest Price Target Changes For Thursday

Financial news for ESPR dated on 2018-05-03: Benzinga's Top Upgrades, Downgrades For May 3, 2018

Financial news for ESPR dated on 2018-05-03: Benzinga Pro's Most-Searched Tickers For Morning Of May 3, 2018

Financial news for ESPR dated on 2018-05-03: Analysts Defend Esperion As Shares Sell Off Sharply

Financial news for ESPR dated on 2018-05-03: JP Morgan Downgrades Esperion Therapeutics to Underweight

Financial news for ESPR dated on 2018-05-03: Deutsche Bank Maintains Buy on Esperion Therapeutics, Lowers Price Target to \$75.00

Financial news for ESPR dated on 2018-05-03: 55 Biggest Movers From Yesterday

Financial news for ESPR dated on 2018-05-02: Mid-Afternoon Market Update: Community Health Systems Surges Following Q1 Beat; TC PipeLines Shares Slide

Financial news for ESPR dated on 2018-05-02: Benzinga's Top Analyst Calls From May 2, 2018

Financial news for ESPR dated on 2018-05-02: 43 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ESPR dated on 2018-05-02: Bank of America Downgrades Esperion And Lowers Price Target From \$95 To \$44 As They Believe Death Imbalance May Raise Concern From FDA, Firm Lowers Drug Penetration In Target Patient Population And Decrease Likelihood Of FDA Approval

Financial news for ESPR dated on 2018-05-02: Bank of America Downgrades Esperion Therapeutics to Underperform

Financial news for ESPR dated on 2018-05-02: Traders Circulating Chatter That Bank Of America Downgrades Esperion

Financial news for ESPR dated on 2018-05-02: Esperion Shares Down 31.4% Wed.; Needham Issues Mid-Day Comments In Note, Says 'We Remain Confident in Efficacy and Safety Profile of Bempedoic Acid'; Maintains Strong Buy Rating, \$94 Price Target

Financial news for ESPR dated on 2018-05-02: Mid-Day Market Update: Nanometrics Rises On Earnings Beat; Esperion Therapeutics Shares Drop

Financial news for ESPR dated on 2018-05-02: 'The question is not if \$ESPR will need to run a CVOT. They will, just like \$REGN and \$AMGN. The key question is -- when? \$ESPR bulls believe CVOT will be done post approval. Bears say CVOT before.'-STAT's Adam Feuerstein

Financial news for ESPR dated on 2018-05-02: Esperion Shares Plunge After Cholesterol-Lowering Drug's Phase 3 Results Stir Safety Concerns

Financial news for ESPR dated on 2018-05-02: JMP Out Defending Esperion, Says There's No Concern In Death Imbalance In Phase 3 Long-Term Study Of Bempedoic Acid, Firm Agrees With Management Commentary That Fatalities In Study 1 Weren't Related To

Study Drug

Financial news for ESPR dated on 2018-05-02: Mid-Morning Market Update: Markets Mixed; Apple Earnings Top Expectations

Financial news for ESPR dated on 2018-05-02: UPDATE: Cowen On Esperion: 'Data presented suggests the top line is fine, however mgmt did a poor job communicating details of the imbalances'; Firm Maintains Buy Rating

Financial news for ESPR dated on 2018-05-02: Esperion Shares Down 22.7% For Session, Up 22% From Session Lows; Hearing Cowen Out Defending Stock, Says 'Magnitude Of Move Is Overdone'

Financial news for ESPR dated on 2018-05-02: Esperion Therapeutics Q1 EPS \$(1.73) Misses \$(1.56) Estimate

Financial news for ESPR dated on 2018-05-02: Esperion Shares To Resume Trade At 8 a.m. EDT

Financial news for ESPR dated on 2018-05-02: Esperion Reports Top-Line Results From Pivotal Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint, Achieved Added 20% On-Treatment LDL-C Lowering On Background Maximally Tolerated Statin Therapy

Financial news for ESPR dated on 2018-05-02: Esperion Shares Halted News Pending

Financial news for ESPR dated on 2018-03-27: Chardan Capital Maintains Neutral on Esperion Therapeutics, Raises Price Target to \$100.00

Financial news for ESPR dated on 2018-03-27: Esperion Phase 2 Study of Bempedoic Acid Met its Primary Endpoint

Financial news for ESPR dated on 2018-03-26: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for ESPR dated on 2018-03-12: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for ESPR dated on 2018-03-07: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ESPR dated on 2018-03-07: Esperion Shares To Resume Trade At 8 a.m. EST

Financial news for ESPR dated on 2018-03-07: Esperion Therapeutics to Resume Trading at 8:00 AM ET

Financial news for ESPR dated on 2018-03-07: Esperion Reports Phase 3 Study Of 1002-048 Has Met Primary Endpoint With LDL-C Lowering Totaling 28% With $p < 0.001$

Financial news for ESPR dated on 2018-03-07: Esperion Shares Halted News Pending

Financial news for ESPR dated on 2018-03-05: 7 Biotech Stocks With Clinical Trial Outcomes In March

Financial news for ESPR dated on 2018-02-21: UBS Maintains Neutral on Esperion Therapeutics, Raises price target to \$90.00

Financial news for ESPR dated on 2018-02-21: JP Morgan Maintains Neutral on Esperion Therapeutics, Raises price target to \$65.00

Financial news for ESPR dated on 2018-02-20: Esperion Reports Q4 EPS \$(1.44) vs \$(1.79) Est.

Financial news for ESPR dated on 2018-01-25: 42 Biggest Movers From Yesterday

Financial news for ESPR dated on 2018-01-22: Citi Downgrades Esperion As Hope Of Acquisition Dwindles

Financial news for ESPR dated on 2018-01-22: Citigroup Downgrades Esperion Therapeutics to Neutral, Raises Price Target to \$96.00

Financial news for ESPR dated on 2018-01-17: Credit Suisse Initiates Coverage On Esperion Therapeutics with Outperform Rating, Announces \$103.00 Price Target

Financial news for ESPR dated on 2018-01-05: BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Financial news for ESPR dated on 2018-01-05: Bank of America Upgrades Esperion

Therapeutics to Buy

Financial news for ESPR dated on 2017-11-07: Esperion Therapeutics Q3 EPS \$(1.86) vs \$(1.79) Est.

Financial news for ESPR dated on 2017-11-06: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill, Top-Line Results Expected by the Fourth Quarter of 2018

Financial news for ESPR dated on 2017-10-18: Lightning Round: Jim Cramer Gives His Opinion On Delta, Sangamo, Kinder Morgan And More

Financial news for ESPR dated on 2017-10-17: Esperion Therapeutics Holding Analyst/Investor Day Today

Financial news for ESPR dated on 2017-10-16: The Week Ahead: Earnings, Earnings, And More Earnings

Financial news for ESPR dated on 2017-08-21: Meditor Group Reports 8.2% Stake In Esperion Therapeutics

Financial news for ESPR dated on 2017-08-09: Benzinga's Top Upgrades, Downgrades For August 9, 2017

Financial news for ESPR dated on 2017-08-09: The Market In 5 Minutes

Financial news for ESPR dated on 2017-08-09: Jefferies Upgrades Esperion Therapeutics to Buy

Financial news for ESPR dated on 2017-08-09: Jefferies Upgrades Esperion to Buy from Hold; Raises PT to \$85 from \$55

Financial news for ESPR dated on 2017-08-08: Esperion Reports Offering Of \$150M In Common Stock

Financial news for ESPR dated on 2017-08-08: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for ESPR dated on 2017-08-08: Esperion Sees FY17 Net Cash Used In Operating Activities ~\$125M-\$135M

Financial news for ESPR dated on 2017-08-08: Esperion Therapeutics Reports Q2 EPS \$(1.92) vs \$(1.61) Est.

Financial news for ESPR dated on 2017-08-08: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ESPR dated on 2017-08-08: Esperion Pharma Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin Meets Primary Endpoint

Financial news for ESPR dated on 2017-07-26: Esperion Announces Initiation Of Phase 2 Study of Bempedoic Acid Added-On To PCSK9 Inhibitor

Financial news for ESPR dated on 2017-07-11: Jefferies Initiates Coverage On Esperion Therapeutics with Hold Rating, Announces \$55.00 Price Target

Financial news for ESPR dated on 2017-06-28: Benzinga's Option Alert Recap From June 28

Financial news for ESPR dated on 2017-06-28: Option Alert: Esperion Dec 27 Put; 2000 @Bid @\$1.07; Ref=\$48.21

Financial news for ESPR dated on 2017-06-26: Esperion Announces FDA Confirmation Of Regulatory Pathway To Approval For Bempedoic Acid and Ezetimibe

Financial news for ESPR dated on 2017-06-23: Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold

Financial news for ESPR dated on 2017-06-23: Deutsche Bank Initiates Coverage On Esperion Therapeutics with Buy Rating, Announces \$48.00 Price Target

Financial news for ESPR dated on 2017-06-16: Esperion Drops to Low of \$32.60 on Volume

Financial news for ESPR dated on 2017-05-22: Esperion Therapeutics Says a Report With Inaccurate Information was Issued Last Thursday

Financial news for ESPR dated on 2017-05-22: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for ESPR dated on 2017-05-19: Benzinga's Option Alert Recap From May 19

Financial news for ESPR dated on 2017-05-04: Esperion Reports Q1 EPS \$(1.80) vs \$(0.65) In Same Qtr. Last Year

Financial news for ESPR dated on 2017-04-12: Esperion Shares Make Near-Term Parabolic Move Over \$38.50 Level; Stock Off Session Highs But Still Up 2.2% for Session; Hearing MoneyShow Blog Has Mentioned Name Positively

Financial news for ESPR dated on 2017-04-10: Cardiovascular Players Could Be Eyeing Esperion

Financial news for ESPR dated on 2017-04-10: Source Familiar with Matter Tells Benzinga Esperion Therapeutics Could Be Drawing Takeover Interest from Player in Cardiovascular Space

Financial news for ESPR dated on 2017-04-10: Watch These 6 Huge Put Purchases In Monday Trade

Financial news for ESPR dated on 2017-04-07: Benzinga's Option Alert Recap From April 7

Financial news for ESPR dated on 2017-04-07: Option Alert: Esperion Sep 13.0 Puts: 1374 @ ASK \$0.25: 2000 traded vs 2033 OI: Earnings 5/3 Before Open [est] \$35.46 Ref

Financial news for ESPR dated on 2017-03-23: 13G Filing Shows Boxer Capital Reporting 5.3% Stake In Esperion Therapeutics

Financial news for ESPR dated on 2017-03-21: Benzinga's Option Alert Recap From March 21

Financial news for ESPR dated on 2017-03-21: Option Alert: Esperion Sep 22.0 Puts: 500 @ ASK \$1.00: 767 traded vs 881 OI: Earnings 5/3 Before Open (est) \$39.85 Ref

Financial news for ESPR dated on 2017-03-20: Esperion Therapeutics Rockets 70% Higher After Big Selloff

Financial news for ESPR dated on 2017-03-20: Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide

Financial news for ESPR dated on 2017-03-20: Needham Raises Target on Esperion Therapeutics from \$25 to \$58

Financial news for ESPR dated on 2017-03-20: 12 Biggest Mid-Day Gainers For Monday

Financial news for ESPR dated on 2017-03-20: Mid-Day Market Update: Nektar Surges After Positive Results From NKTR-181 Study; Cerulean Pharma Shares Drop

Financial news for ESPR dated on 2017-03-20: PreMarket Prep Recap, March 20: Major Volatility At Friday's Close And Why Disney Is In For A Big Quarter

Financial news for ESPR dated on 2017-03-20: In Response To Adam Feuerstein's Tweet On Esperion, Forbes Reporter Matthew Herper Tweets: @adamfeuerstein looks mostly like a correction to Friday to me.

Financial news for ESPR dated on 2017-03-20: Adam Feuerstein Tweets: \$ESPR reaction to widely expected regulatory news this morning is puzzling.

Financial news for ESPR dated on 2017-03-20: Mid-Morning Market Update: Markets Mostly Flat; Washington Companies Proposes To Acquire Dominion Diamond

Financial news for ESPR dated on 2017-03-20: Credit Suisse Upgrades Esperion Therapeutics to Neutral

Financial news for ESPR dated on 2017-03-20: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for ESPR dated on 2017-03-20: Esperion Therapeutics Receives FDA Confirmation Regarding Regulatory Pathway To Approval For An LDL-C Lowering Indication For Bempedoic Acid

Financial news for ESPR dated on 2017-03-17: 20 Biggest Mid-Day Losers For Friday

Financial news for ESPR dated on 2017-03-17: Esperion Falls Victim To Amgen's Poor Repatha Results

Financial news for ESPR dated on 2017-03-07: Esperion Therapeutics Reports Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin

Financial news for ESPR dated on 2017-02-28: Citigroup Upgrades Esperion Therapeutics To Buy

Financial news for ESPR dated on 2017-02-23: 18 Biggest Mid-Day Gainers For Thursday

Financial news for ESPR dated on 2017-02-22: Esperion Reports Q4 EPS \$(1.29) vs. \$(1.22) Est.

Financial news for ESPR dated on 2017-02-16: Esperion Pops to High of \$23 on Volume

Financial news for ESPR dated on 2017-02-07: Esperion Surge May Be Fueled By Repatha Short Squeeze

Financial news for ESPR dated on 2017-02-02: Esperion, Medicines Company Shares Higher After-Hours; Amgen Said Repatha Reduces Risk of Cardiovascular Events

Financial news for ESPR dated on 2017-01-08: Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid

Financial news for ESPR dated on 2016-11-16: BZ NOTE: Volatility In Esperion Therapeutics May Be Due To Company Presentation At Stifel Healthcare Conf. Today

Financial news for ESPR dated on 2016-11-16: Stifel Healthcare Conference Continues Today

Financial news for ESPR dated on 2016-11-16: Esperion Spikes to High of \$11.31 on Volume

Financial news for ESPR dated on 2016-11-03: Esperion Therapeutics Reports Q3 EPS \$(0.77) vs. Est. \$(0.82)

Financial news for ESPR dated on 2016-11-01: 10 Stocks That Plummeted The Past Three Days On Increasing Volume

Financial news for ESPR dated on 2016-10-14: 10 Biggest Price Target Changes For Friday

Financial news for ESPR dated on 2016-10-14: Credit Suisse Changes Its View On Esperion Therapeutics, Raises Price Target

Financial news for ESPR dated on 2016-10-13: Top-Line Data For Esperion's Bempedoic Acid Creates Question About Whether There Is A Place In The Market For It

Financial news for ESPR dated on 2016-10-13: 10 Biggest Mid-Day Gainers For Thursday

Financial news for ESPR dated on 2016-10-13: Benzinga's Volume Movers

Financial news for ESPR dated on 2016-10-13: Esperion Therapeutics Reports Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose, Met Primary Endpoint

Financial news for ESPR dated on 2016-10-10: Adam Feuerstein @adamfeuerstein @measured_moves @AndyBiotech Tweet: \$ESPR spox tells me study data coming very soon, no specific explanation for missing the September timeline.

Financial news for ESPR dated on 2016-09-27: 13G from BB Biotech on Esperion Therapeutics Shows New 5.1% Stake

Financial news for ESPR dated on 2016-09-26: Bio Pharma Companies Expected To Report Data By Friday Sept. 30 Include Genocera Biosciences, SCYNEXIS, Threshold Pharmaceuticals, Arbutus Biopharma, Cytori Therapeutics, Esperion Therapeutics, Mesoblast, Marinus Pharmaceuticals, & Syndax Pharmaceuticals

Financial news for ESPR dated on 2016-08-18: 11 Biopharma CEOs To Follow On Twitter

Financial news for ESPR dated on 2016-08-11: Esperion Therapeutics Sells off on Volume

Financial news for ESPR dated on 2016-08-04: Esperion Therapeutics Reports Q2 \$(0.62) vs. Est. \$(0.78)

Financial news for ESPR dated on 2016-07-11: These Five Stocks Have Gotten A Lot Of Attention From Analysts

Financial news for ESPR dated on 2016-07-07: Director McGovern Buys 5,000 Shares of Esperion Therapeutics @\$10.00/Share -Form 4

Financial news for ESPR dated on 2016-07-05: UBS Downgrades Esperion Therapeutics From Buy To Neutral

Financial news for ESPR dated on 2016-07-05: Benzinga's Top Downgrades

Financial news for ESPR dated on 2016-07-05: Wallachbeth Downgrades Esperion Therapeutics to Hold

Financial news for ESPR dated on 2016-06-30: Benzinga's Volume Movers

Financial news for ESPR dated on 2016-06-30: 5 Largest Price Target Changes For Thursday

Financial news for ESPR dated on 2016-06-30: Benzinga's Top Downgrades

Financial news for ESPR dated on 2016-06-30: Esperion Price Target Cut At Citi On U.S. Approval Likelihood

Financial news for ESPR dated on 2016-06-29: Analysts At Chardan See A 'Pattern Of Missed Guidance' For Esperion Therapeutics

Financial news for ESPR dated on 2016-06-29: Sharp Downside In Esperion Shares May Be An Overreaction

Financial news for ESPR dated on 2016-06-29: Esperion Therapeutics Downgraded By JPMorgan After Concerns With FDA Endpoint

Financial news for ESPR dated on 2016-06-29: Mid-Afternoon Market Update: Dow Jumps Over 250 Points; Diamond Resorts Shares Climb Following Apollo Deal

Financial news for ESPR dated on 2016-06-29: 7 Biggest Mid-Day Losers For Wednesday

Financial news for ESPR dated on 2016-06-29: Mid-Day Market Update: Crude Oil Surges 3%; Galena Biopharma Shares Tumble

Financial news for ESPR dated on 2016-06-29: Barclays Downgrades Esperion Therapeutics to Equal-weight, Lowers PT to \$13.00

Financial news for ESPR dated on 2016-06-29: Stocks Hitting 52-Week Lows

Financial news for ESPR dated on 2016-06-29: Mid-Morning Market Update: Markets Open Higher; General Mills Profit Tops Expectations

Financial news for ESPR dated on 2016-06-29: Esperion Therapeutics Downgraded On Regulatory Concerns By Credit Suisse

Financial news for ESPR dated on 2016-06-29: 8 Largest Price Target Changes For Wednesday

Financial news for ESPR dated on 2016-06-29: Benzinga's Top Downgrades

Financial news for ESPR dated on 2016-06-29: The Market In 5 Minutes: Swoosh And A Miss

Financial news for ESPR dated on 2016-06-29: 13 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ESPR dated on 2016-06-29: RBC Capital Downgrades Esperion Therapeutics to Sector Perform

Financial news for ESPR dated on 2016-06-29: Credit Suisse Downgrades Esperion Therapeutics to Underperform, Lowers PT to \$10.00

Financial news for ESPR dated on 2016-06-29: JP Morgan Downgrades Esperion Therapeutics to Neutral, Lowers PT to \$15.00

Financial news for ESPR dated on 2016-06-28: 4 Stocks Moving In Tuesday's After-Hours Session: Earnings, Buybacks & FDA Setbacks

Financial news for ESPR dated on 2016-06-28: Esperion Therapeutics Shares Fall 29% After-Hours to \$11.50

Financial news for ESPR dated on 2016-06-28: Esperion Sees 2016 FY Cash and Cash Equivalents And Investment Securities At \$220M by December 31/16

Financial news for ESPR dated on 2016-06-28: UPDATE: Esperion Says On Track to Initiate Global Pivotal Phase 3 Studies, CVOT in Q4

Financial news for ESPR dated on 2016-06-28: Esperion Offers Clinical Development, Regulatory Update for Bempedoic Acid

Financial news for ESPR dated on 2016-06-28: Adam Feuerstein @adamfeuerstein Tweet: Is there a reason for \$ESPR to hold a call tonight?

Financial news for ESPR dated on 2016-05-04: Esperion Therapeutics Reports Q1 EPS \$(0.65) vs. Est. \$(0.74)

Financial news for ESPR dated on 2016-03-02: Esperion Therapeutics Surges 13%

Financial news for ESPR dated on 2016-03-02: Dir Omenn Buys 5,000 Shares Of Esperion Therapeutics @\$15.28/Share -Form 4

Financial news for ESPR dated on 2016-02-26: Chardan Capital Maintains Neutral on Esperion Therapeutics, Lowers PT to \$13.00

Financial news for ESPR dated on 2016-02-26: Chardan Capital Maintains Neutral on Esperion Therapeutics, Lowers PT to \$13.00

Financial news for ESPR dated on 2016-02-25: Esperion Therapeutics reports Q4 EPS \$(0.58) vs \$(0.63) Est.; Sees FY16 Cash, Cash Equivalents ~\$200M at Year End

Financial news for ESPR dated on 2016-02-24: Barclays Maintains Overweight on Esperion Therapeutics, Lowers PT to \$28.00

Financial news for ESPR dated on 2016-01-13: Esperion Therapeutics Reports Start of Phase 3 Clinical Program With Long-Term Safety, Tolerability Study

Financial news for ESPR dated on 2016-01-12: UPDATE: Esperion Therapeutics Expects To Announce Top-Line Results By Mid-Year

Financial news for ESPR dated on 2016-01-12: Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy

Financial news for ESPR dated on 2015-12-22: S-3 from Esperion Therapeutics Shows Registration for \$250M Mixed Securities Shelf Offering

Financial news for ESPR dated on 2015-11-04: Chardan: Time To Buy The Medicines Co.

Financial news for ESPR dated on 2015-10-13: JMP Analyst Says Eli Lilly's CETP Failure Positive For Esperion Therapeutics ETC-1002 Oral Candidate, States Strategic Value Of Asset Has Increased

Financial news for ESPR dated on 2015-10-12: UPDATE: Chardan's Amusa Highlights Bull vs Bear Case for Esperion, Sees the Latter as 'More Important'

Financial news for ESPR dated on 2015-10-12: Chardan Capital's Amusa on Esperion Following Evacetrapib Discontinuation: '...by increasing the likelihood of regulatory scrutiny on ETC-1002, the evacetrapib failure reduces the chance ETC-1002 gets there...'

Financial news for ESPR dated on 2015-10-12: Benzinga's Volume Movers

Financial news for ESPR dated on 2015-10-12: Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives

Financial news for ESPR dated on 2015-10-12: Morning Market Gainers

Financial news for ESPR dated on 2015-10-12: UPDATE: Shares of Esperion Therapeutics Trading Up ~14% Following Discontinuation of Lilly's Evacetrapib

Financial news for ESPR dated on 2015-10-12: TheStreet's Adam Feuerstein Recently Tweets: 'Watch \$ESPR' on the Heels of Eli Lilly Discontinuation of Evacetrapib

Financial news for ESPR dated on 2015-10-12: Esperion Shares Trading Higher To \$28.50/Share, Up 14.9% Premarket Following Eli Lilly Development Discontinuation For Evacetrapib

Financial news for ESPR dated on 2015-10-03: 5 Stocks Moving On Friday's After-Hours: From Barracuda To TerraForm

Financial news for ESPR dated on 2015-09-30: Morning Market Gainers

Financial news for ESPR dated on 2015-09-30: Esperion Therapeutics +11 Premarket Following Chardan Upgrade to Neutral

Financial news for ESPR dated on 2015-09-29: Esperion Therapeutics: Chardan Maintains

Negative Bias, Additional Concerns Over ETC-1002 Profile - Says Optimism May Overshoot Reality Of Datasets

Financial news for ESPR dated on 2015-09-29: Chardan Capital Upgrades Esperion Therapeutics to Neutral, Lowers PT to \$18.00

Financial news for ESPR dated on 2015-09-29: Morning Market Losers

Financial news for ESPR dated on 2015-09-29: Benzinga's Top #PreMarket Losers

Financial news for ESPR dated on 2015-09-29: Esperion Therapeutics -16% Premarket Following Update on ETC-1002 Global Phase 3 Strategy; Analyst PT Cuts

Financial news for ESPR dated on 2015-09-28: Esperion Therapeutics Gives Further Updates on ETC-1002 Global Phase 3 Strategy Following Receipt of End-of-Phase 2 Meeting Minutes

Financial news for ESPR dated on 2015-08-19: Benzinga's Top Downgrades

Financial news for ESPR dated on 2015-08-19: Morning Market Losers

Financial news for ESPR dated on 2015-08-19: Benzinga's Top #PreMarket Losers

Financial news for ESPR dated on 2015-08-19: Needham Downgrades Esperion Therapeutics to Strong Buy

Financial news for ESPR dated on 2015-08-18: Morning Market Gainers

Financial news for ESPR dated on 2015-08-18: Benzinga's Top #PreMarket Gainers

Financial news for ESPR dated on 2015-08-18: Watch These After-Hours Movers On Tuesday

Financial news for ESPR dated on 2015-08-17: Esperion Offers Update on ETC-1002 Development Program: Says On Track to Begin Phase 3 Trial by Year End '15

Financial news for ESPR dated on 2015-08-10: Needham Upgrades Esperion Therapeutics to Strong Buy

Financial news for ESPR dated on 2015-08-07: Chardan: Esperion Therapeutics Still A Sell

Financial news for ESPR dated on 2015-08-03: 5 Biotechs With Catalysts Coming This Week

Financial news for ESPR dated on 2015-07-28: Chardan Reiterates Sell On Esperion, Cites 'Lack Of Visibility' And 'Possibility Of Declining Efficacy'

Financial news for ESPR dated on 2015-07-28: Benzinga's Top #PreMarket Gainers

Financial news for ESPR dated on 2015-07-28: Esperion +6% as Co Reported Top-Line Phase 2 Results for ETC-1002

Financial news for ESPR dated on 2015-07-28: Esperion Therapeutics Reports Top-Line Phase 2 Results for ETC-1002 Met Primary Endpoint

Financial news for ESPR dated on 2015-07-26: Biotech Stocks Falling Broadly, Here's Why And How Much

Financial news for ESPR dated on 2015-07-24: Traders Attributing Esperion Price Drop To Regeneron News

Financial news for ESPR dated on 2015-07-24: Esperion Spikes Lower

Financial news for ESPR dated on 2015-07-08: Chardan Reiterates Sell On Esperion Therapeutics, Sees At Least 6 Reasons To Beware

Financial news for ESPR dated on 2015-07-07: Esperion Therapeutics Shares +4% Premarket After Co Announces Removal of 240 mg Partial Clinical Hold for ETC-1002

Financial news for ESPR dated on 2015-07-07: Esperion Therapeutics Announces Removal of 240 mg Partial Clinical Hold for ETC-1002

Financial news for ESPR dated on 2015-06-30: 5 Biotech Stocks On Deck With The FDA

Financial news for ESPR dated on 2015-06-30: Esperion Shares Spike to High on Volume

Financial news for ESPR dated on 2015-06-25: JP Morgan Initiates Esperion Therapeutics With Overweight

Financial news for ESPR dated on 2015-06-25: Benzinga's Top Initiations

Financial news for ESPR dated on 2015-06-25: JP Morgan Initiates Coverage on Esperion Therapeutics at Overweight, Announces \$130.00 PT

Financial news for ESPR dated on 2015-06-24: Benzinga's Top Downgrades

Financial news for ESPR dated on 2015-06-24: Credit Suisse Downgrades Esperion Therapeutics To Neutral

Financial news for ESPR dated on 2015-06-24: Credit Suisse: Esperion Therapeutics' Long-Term Potential Is 'Robust,' But More Clarity Needed

Financial news for ESPR dated on 2015-06-24: Credit Suisse Downgrades Esperion Therapeutics to Neutral, Lowers PT to \$86.00

Financial news for ESPR dated on 2015-06-23: Credit Suisse Assumes Esperion Therapeutics at Neutral, Lowers \$86.00 PT

Financial news for ESPR dated on 2015-06-23: Netflix Goes 7-For-1; Vanda Pharma And FibroGen Lead Tuesday's After-Hours Movers

Financial news for ESPR dated on 2015-06-15: Esperion Therapeutics Announces the Appointment of Scott Braunstein, M.D. to Board of Directors

Financial news for ESPR dated on 2015-06-10: Morning Market Losers

Financial news for ESPR dated on 2015-06-10: Benzinga's Top #PreMarket Losers

Financial news for ESPR dated on 2015-06-03: Esperion Shares Rise 5% Premarket; JMP Securities Raised PT from \$121 to \$177, Maintaining Outperform Rating

Financial news for ESPR dated on 2015-05-22: Morning Market Losers

Financial news for ESPR dated on 2015-05-21: 4 SMID-Cap Biotechs Barclays Just Confessed It Loves

Financial news for ESPR dated on 2015-05-21: Barclays Initiates Coverage on Esperion Therapeutics at Overweight, Announces \$150.00 PT

Financial news for ESPR dated on 2015-05-21: Barclays Initiates Coverage on Esperion Therapeutics at Overweight, Announces \$150.00 PT

Financial news for ESPR dated on 2015-05-19: 7 Biotech Stocks Moving Off The UBS Healthcare Conference

Financial news for ESPR dated on 2015-05-07: Esperion Therapeutics Reports Q1 Loss of \$0.56/Share; 8-K Shows Co. Expecting Topline Results from Phase 2 Study of ETC-1002-014 by Mid '15

Financial news for ESPR dated on 2015-04-21: 3 Diverse Stocks This Expert Is Watching (In 3 Charts)

Financial news for ESPR dated on 2015-04-13: Esperion Shares Spike Higher on Volume

Financial news for ESPR dated on 2015-04-06: These 5 Stocks Have More Than Doubled In 2015

Financial news for ESPR dated on 2015-04-01: Morning Market Gainers

Financial news for ESPR dated on 2015-04-01: Here's Why Esperion Therapeutics Is Rocketing Higher

Financial news for ESPR dated on 2015-04-01: UBS Initiates Esperion Therapeutics With Buy

Financial news for ESPR dated on 2015-04-01: Benzinga's Top Initiations

Financial news for ESPR dated on 2015-04-01: Benzinga's Top #PreMarket Gainers

Financial news for ESPR dated on 2015-04-01: UBS Initiates Coverage on Esperion Therapeutics at Buy, Announces \$140.00 PT

Financial news for ESPR dated on 2015-03-27: Is Esperion Therapeutics Worth \$130? This Analyst Thinks So

Financial news for ESPR dated on 2015-03-27: Morning Market Gainers

Financial news for ESPR dated on 2015-03-27: Citigroup Assumes Esperion Therapeutics at Buy, Announces \$130.00 PT

Financial news for ESPR dated on 2015-03-25: 13D Filing Shows Esperion Therapeutics Holder Domain Partners Raises Stake From 10.29% To 11.2%

Financial news for ESPR dated on 2015-03-21: Pro: Esperion Therapeutics Shares Could Double

Financial news for ESPR dated on 2015-03-19: Benzinga's Volume Movers

Financial news for ESPR dated on 2015-03-19: Morning Market Gainers

Financial news for ESPR dated on 2015-03-19: Benzinga's Top #PreMarket Gainers

Financial news for ESPR dated on 2015-03-19: Esperion Therapeutics Shares Fall 2% Premarket Following Pricing of 1.75M Share Offering @\$100.00/Share

Financial news for ESPR dated on 2015-03-17: Tuesday's After-Hours Movers: Oracle, Papa Murphy's And More

Financial news for ESPR dated on 2015-03-17: Esperion Therapeutics Announces \$150M Offering

Financial news for ESPR dated on 2015-03-17: Benzinga's Volume Movers

Financial news for ESPR dated on 2015-03-17: Esperion Therapeutics Says ETC-1002-009 Study Met Primary Endpoint

Financial news for ESPR dated on 2015-02-09: Stocks Hitting 52-Week Highs

Financial news for ESPR dated on 2015-02-03: Esperion Therapeutics Spokesperson Says Co Pleased With PT Raise by Credit Suisse, Says Recognizes Value We Think We Have in ETC-1002

Financial news for ESPR dated on 2015-02-03: Mid-Morning Market Update: Markets Open Higher; AutoNation Profit Beats Views

Financial news for ESPR dated on 2015-02-03: Benzinga's Volume Movers

Financial news for ESPR dated on 2015-02-03: Stocks Hitting 52-Week Highs

Financial news for ESPR dated on 2015-02-03: Morning Market Gainers

Financial news for ESPR dated on 2015-02-03: Esperion Therapeutics Shares Rise ~18% Premarket on Credit Suisse Comments that Co is Likely Acquisition Target, Raises PT to \$100 from \$41

Financial news for ESPR dated on 2015-02-03: Credit Suisse Sees Esperion Therapeutics Likely Acquisition, Raises PT To \$100 From \$41

Financial news for ESPR dated on 2015-01-21: Bank of America Upgrades Esperion Therapeutics to Buy, Raises PT to \$60.00

Financial news for ESPR dated on 2015-01-05: UPDATE: JMP Securities Reiterates On Esperion Therapeutics On Minimal Risks

Financial news for ESPR dated on 2014-12-30: Esperion Therapeutics Declines Comment on Move in Share Price

Financial news for ESPR dated on 2014-12-22: S-3 from Esperion Therapeutics Shows Registration for \$200M Mixed Securities Shelf Offering

Financial news for ESPR dated on 2014-12-04: Credit Suisse Maintains Outperform on Esperion Therapeutics, Raises PT to \$41.00

Financial news for ESPR dated on 2014-10-27: Benzinga's Volume Movers

Financial news for ESPR dated on 2014-10-16: Morning Market Losers

Financial news for ESPR dated on 2014-10-16: Benzinga's Top #PreMarket Losers

Financial news for ESPR dated on 2014-10-15: Esperion Therapeutics Prices 4.25M Share Offering @\$20.00/Share

Financial news for ESPR dated on 2014-10-14: Esperion Therapeutics Announces \$85M Proposed Public Offering of Common Stock

Financial news for ESPR dated on 2014-10-02: Markets Mixed; Constellation Brands

Posts Downbeat Profit

Financial news for ESPR dated on 2014-10-02: Stocks Hitting 52-Week Highs

Financial news for ESPR dated on 2014-10-02: UPDATE: JMP Securities Reiterates On Esperion Therapeutics Inc Following Positive Trial Results

Financial news for ESPR dated on 2014-10-02: Morning Market Movers

Financial news for ESPR dated on 2014-10-02: UPDATE: Credit Suisse Reiterates On Esperion Therapeutics Inc On Multiple Positive Factors

Financial news for ESPR dated on 2014-10-02: Benzinga's Top #PreMarket Gainers

Financial news for ESPR dated on 2014-10-02: JMP Securities Maintains Market Outperform on Esperion Therapeutics, Raises PT to \$53.00

Financial news for ESPR dated on 2014-10-02: Credit Suisse Maintains Outperform on Esperion Therapeutics, Raises PT to \$38.00

Financial news for ESPR dated on 2014-10-01: UPDATE: Esperion Therapeutics Reports Results of Trial Met Primary Endpoint

Financial news for ESPR dated on 2014-10-01: Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002

Financial news for ESPR dated on 2014-10-01: Esperion Therapeutics Announces Positive Top-Line Phase 2b Results For ETC-1002, An Investigational Therapy For Patients With Hypercholesterolemia

Financial news for ESPR dated on 2014-08-12: Esperion Therapeutics Reports Q2 EPS of \$(0.60), Inline

Financial news for ESPR dated on 2014-08-12: Esperion Therapeutics Says Top-Line Results Expected in Early October from Phase 2B ETC-1002-008 Clinical Trial in Statin Intolerant Patients

Financial news for ESPR dated on 2014-07-24: Esperion Therapeutics Announces Initiation of Phase 2 ETC-1002 Study

Financial news for ESPR dated on 2014-02-26: Esperion Therapeutics to Provide ETC-1002 Program Update; Fourth Quarter and Full Year 2013 Financial Results

Financial news for ESPR dated on 2014-02-13: Shares of Esperion Therapeutics Up ~4% Since 13G Filing from Pfizer Disclosing Unch Position at 6.29%

Financial news for ESPR dated on 2013-11-06: Esperion Therapeutics Reports Q3 EPS of \$(0.34) vs \$(0.40) Est

Financial news for ESPR dated on 2013-08-12: Esperion Therapeutics Reports Q2 GAAP EPS of \$(19.82) Which May Not Compare \$(0.53) Est

Financial news for ESPR dated on 2013-07-22: Credit Suisse Initiates Coverage on Esperion Therapeutics at Outperform, Announces \$23.00 PT

Financial news for ESPR dated on 2013-07-22: UPDATE: Stifel Nicolaus Initiates Esperion Therapeutics at Buy on ETC-1002 Potential

Financial news for ESPR dated on 2013-07-22: Credit Suisse Initiates Coverage on Esperion Therapeutics at Outperform, Announces \$23.00 PT

Financial news for ESPR dated on 2013-07-22: Citigroup Initiates Coverage on Esperion Therapeutics at Buy, Announces \$30.00 PT

Financial news for ESPR dated on 2013-07-22: Stifel Nicolaus Initiates Coverage on Esperion Therapeutics at Buy, Announces \$24.00 PT

Financial news for ESPR dated on 2013-07-11: Esperion Therapeutics, Inc. Announces Exercise of Underwriters' Over-Allotment Option for Initial Public Offering

Financial news for ESPR dated on 2013-06-26: Esperion Therapeutics Shares Open at \$17 After Pricing at \$14, Moving Higher, Now at \$17.23

Financial news for ESPR dated on 2013-06-26: IPO for Esperion Therapeutics to Open for Quote at 10:25AM EDT, Expected to Open at 10:40AM

Financial news for ESPR dated on 2013-06-26: Esperion Therapeutics Prices 5M Share IPO at \$14 per Share

Financial news for ESPR dated on 2013-05-14: Esperion Therapeutics Files \$70M IPO